Finger pushing


PERSPECTIVE: Psychedelic nightmare

Gov. Jared Polis announced on X in late May that our state’s psychedelics program is “fully launched!”

That’s bad news for Colorado and anyone who cares about actually minimizing the harm psychedelics do to people, families and communities.

The governor’s ecstatic tweet referred to the recent regulatory approval from the state Department of Revenue’s Natural Medicine Division (an utter misnomer), OK-ing licenses for growers, manufacturers and other participants in Colorado’s nascent industry.

That, combined with a state Department of Public Health and Environment certification of a psilocybin product testing center and licensure of facilitators — who provide support during psilocybin “therapy” — by the Department of Regulatory Agencies, means all systems go for growing and distributing and consuming a wide spread of psychedelics.

Aside from the fact that no one has a clue what dosage is required to treat any of the ailments for which these products will be used, what will it look like? The data suggest dark clouds on the horizon.

Take psilocybin. Yes, advocates claim it can provide a host of benefits for depression, anxiety, post-traumatic stress disorder; the drug’s most hardcore evangelists say it will even bring you closer to God.

Yet given what the science says, this news should worry every Coloradan — and everyone everywhere else in America, since our state has played a leading role in helping normalize bad drug policy nationwide.

Indeed, noting what the science doesn’t say would be more accurate.

Consider a 2024 publication from researchers in Ireland and Canada, a review of nearly 200 published psilocybin studies, and 80 ongoing ones. Their findings should have put the brakes on efforts at the local, state and federal level to greenlight legal psilocybin.

Almost half the studies in which participants ingested psilocybin did not use a control group; i.e., there was no meaningful baseline against which to compare the results of the “treatment.”

The median number of study participants was 22; within that, the median number of those who had taken the drug was 18.

Almost 40% of the studies relied for their primary outcome assessment — the tool by which results of taking psilocybin are observed and categorized — on self-reporting and questionnaires as opposed to more objective clinical measures.

The paltriness of the sample sizes and the subjectivity of the outcome assessments means the results should not serve as any kind of guide for governmental regulation designating dangerous chemicals like psilocybin as potential medicine. As does the fact that the review logged precisely one report of an adverse advent; for anyone who’s seen the damage psilocybin can do up close, that figure defies credulity.

Then there is the uncomfortable fact that almost 46% of the studies in this meta-analysis reported potential conflicts of interest, while 16% did not report whether they were conflicted.

Yes, conflicts of interest don’t automatically invalidate any individual piece of research.

But considering the stakes here — the commercialization of powerful hallucinogens — those numbers should scare the heck out of advocates and the communities Colorado’s program is set to harm (and raise journalistic hackles, too).

Especially since the wider psychedelics project in our state is riddled with conflicts of interest: Kevin Matthews, who served as president of Denver’s Psilocybin Mushroom Review Panel, was revealed to be working for the lobbying arm of the PAC that spent millions of dollars pushing through Prop. 122, which decriminalized psilocybin (and DMT, and ibogaine, and nonpeyote mescaline).

And Denver has seen an uptick in emergency room visits for psilocybin since decriminalizing the substance a few years ago.

Given the murk of regulatory capture and the dubious science around the benefits, it’s important to remember what we do know about psilocybin and other psychedelics.

And there’s no better illustration of that than the disturbing case of Joseph Emerson.

Emerson is a former Alaska Airlines pilot facing 83 charges of reckless endangerment after he attempted in 2023 to down a plane while riding in the cockpit. He allegedly tried to pull the emergency engine shut-off handles midair and later attempted to open a cabin door.

Why would Emerson, an experienced commercial pilot, try to kill himself and everyone on board that flight?

In his words, he was “fully convinced” that everything — the plane, his existence, and the consequences of his actions — was not “real.”

And — just by coincidence, of course — Emerson had taken psilocybin mushrooms during a trip with some friends two days before flying; by his own report he still didn’t feel quite right as he prepped to get on that fateful plane ride.

That feeling of not-rightness exploded into what was seconds away from becoming a horrific tragedy; it sounds like a textbook case of a side effect of psychedelic use called hallucinogen persisting perception disorder (HPPD).

The disorder is a DSM-described complex of symptoms that occur when the reality-distorting effects of hallucinogens linger on long after the instance of use.

Its clinical presentation can include haloes and visual trailing, object-size distortion, and seeing nonexistent movement — as well as deep-seated, near-psychotic feelings of unreality like the ones Emerson reported suffering in the hours and minutes before almost killing himself and dozens of others.

A study in 2023 of 608 psychedelic users suggests that this persistence issue is, well, persistent.

Almost 17% of the users in the study experienced lasting effects for more than three years; almost 32% had effects last more than one year; of the adverse lasting effects the study identified, 76% of participants had emotional problems; 52% had cognitive problems; and 50% began to have doubts about reality itself.

In the words of one participant: taking these drugs “left a legacy of confusion about what deeper model of reality to use, and repeated experiences of flipping between these models at different times.”

In fact, HPPD and related issues are such a serious concern with psilocybin and other psychedelics that a clinic has opened in Berlin devoted to treating them (albeit one run on misguided “harm reduction” principles).

That’s what Gov. Polis is so gung-ho on social media about. That’s what our state’s legislature and regulatory regime have given their blessing.

Psilocybin and other psychedelic drugs are on Schedule 1 for a reason: High abuse potential, no accepted medical use, and a lack of accepted safety for use.

The science around that hasn’t changed; all the evidence suggests that these drugs will go on endangering users and the people around them long after the moment of use has ended.

Imagine, if you will, a bus driver having an episode of HPPD midrun down a busy street.

A kindergarten teacher suffering an Emerson-style breakdown in the same room as your 5-year-old.

A doctor losing contact with reality while doing a heart bypass on your father.

Using state power and capacity to serve end-running federal guidelines, accepted science, and common sense — all to enable social disorder and personal harm — is not something any politician should be so giddily proud of.

Luke Niforatos is executive vice president of Smart Approaches to Marijuana and of the Foundation for Drug Policy Solutions.

Luke Niforatos
Luke Niforatos
ODPE, a strain of psychedelic mushrooms, sits in the back room of Lyman Support Centers in Denver, which offers psychedelic mushrooms as microbuses, lotions, and other products as a therapeutic service. A new study from Denver Health has found that use of psilocybin has increased from 25 million in 2019 to more than 31 million in 2023, putting it second only to cannabis. (StephenSwoffordPhotographerstephen.swofford@gazette.comhttps://secure.gravatar.com/avatar/1ddcaf11c5d70eaa58546ddc4e038687?s=100&d=mm&r=g)
ODPE, a strain of psychedelic mushrooms, sits in the back room of Lyman Support Centers in Denver, which offers psychedelic mushrooms as microbuses, lotions, and other products as a therapeutic service. A new study from Denver Health has found that use of psilocybin has increased from 25 million in 2019 to more than 31 million in 2023, putting it second only to cannabis. (StephenSwoffordPhotographerstephen.swofford@gazette.comhttps://secure.gravatar.com/avatar/1ddcaf11c5d70eaa58546ddc4e038687?s=100&d=mm&r=g)
In 2019, voters made Denver the first U.S. city to decriminalize the use of psilocybin, the psychedelic substance in certain mushrooms. (the Associated Press file)
In 2019, voters made Denver the first U.S. city to decriminalize the use of psilocybin, the psychedelic substance in certain mushrooms. (the Associated Press file)
Tags columnists


Welcome Back.

Streak: 9 days i

Stories you've missed since your last login:

Stories you've saved for later:

Recommended stories based on your interests:

Edit my interests